Lignocaine, is a medicine, mainly used in the treatment of ventricular tachycardia, arrhythmia and to perform nerve blocks. However local anaesthetic remains the largest application of Lignocaine. The development of dentistry has led to the development of the market in the past. Lignocaine has found use as a cough suppressor which reduces cough reflex. Lidocaine mechanism of action is by blocking sodium channels and thus preventing local neurons signal the brain. Lidocaine is also an antiarrhythmic medication which reduces the contraction of heart.
Ask For Free Sample Report @ https://www.marketresearchfuture.com/sample_request/4558
The lidocaine sales are suffering from market fragmentation, which has put pressure on the price margins. The generics have captured the major market share which, coupled with the low market price margins, has resulted in large players quitting the market. Other market constrains are adverse side effects of lidocaine use are sleepiness, muscle twitching, confusion, changes in vision, numbness, tingling, vomiting, low blood pressure and an irregular heart rate etc.
Thus, there is presence of huge production capacity which has also put pressure on prices. However, product development in the form of formulation development has been successful as exemplified by inhalation sprays. Moreover the high volume and low value nature of lidocaine has restricted the market to small players.
Cost of the product will be a decisive factor for the Asia Pacific lidocaine market especially in the poor countries of Asia Pacific.
Asia Pacific Lignocaine Market Players
Some of the key players profiled in the report are Sambria Pharmaceuticals, Pierrel S.p.A., Galen US Inc., Mahendra Chemicals, Iwaki Seiyaku Co., Ltd., Biotechnica Pharma Asia Pacific, Harman Finochem Limited, Endo International, and others.